Cardiovascular Disease
Conditions
Keywords
Cardiovascular, Flow-Mediated Vasodilation (FMD), Pulse Perfusion-Mediated Vasodilation (PPMV), Endothelial Function, Heart Failure, Local Distensibility, Arterial Stiffening, Augmentation Index (AI), Aging, Isolated Systolic Hypertension, Advanced Glycation Endproducts, Vascular Stiffness
Brief summary
Determine whether increasing arterial distensibility by decreasing advanced glycation end-product (AGE) cross-link components of vascular stiffness improves (a) endothelial-mediated vasoreactivity at rest, as assessed by flow-mediated vasodilation (FMD), and (b) endothelial-mediated vasoreactivity after exercise, as assessed by pulse perfusion-mediated vasodilation (PPMV).
Detailed description
* Explore several independent variables as potential independent predictors of vascular stiffness and endothelial function. These parameters include patient age, body mass index, gender, renal disease, history of cardiovascular disease, serum cholesterol, and antihypertensive medication use. * Provide insight into nitric oxide-dependent endothelial function in the setting of increased arterial stiffness by determination of substances in the nitric oxide signaling pathway (specifically, levels of serum cGMP; serum nitrate and nitrite; and serum asymmetric dimethylarginine \[ADMA\], an endogenous inhibitor of nitric oxide synthase). * Provide insight into changes in AGE levels and collagen metabolism in response to alagebrium therapy \[specifically, AGEs: pentosidine, carboxymethyllysine, carboxyethyllysine, furosine; Collagen markers: procollagen I carboxyterminal propeptide (PICP), procollagen type I N terminal propeptide (PINP), cross-linked carboxyterminal telopeptide of Type I collagen (ICTP), n-terminal propeptide of type III procollagen (PIIINP)\]. * Provide insight into changes in markers of inflammation in response to alagebrium therapy \[specifically, free and total serum matrix metalloproteinase-1(MMP-1), free tissue inhibitor of metalloproteinase 1 (TIMP1), intercellular adhesion molecule-1 (ICAM), P-selectin, von Willebrand factor (vWf), interleukin-6 (IL-6), and high-sensitivity C reactive protein (hs CRP)\].
Interventions
Sponsors
National Institutes of Health (NIH)
Synvista Therapeutics, Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female 50 years of age or greater. 2. Diagnosed with systolic hypertension (systolic blood pressure \>140 mm Hg and (less than or equal to) 200 mm Hg, and a diastolic blood pressure (less than or equal to) 95 mm Hg) and elevated pulse pressure (systolic blood pressure \[SBP\] minus diastolic blood pressure \[DBP\] greater than 60 mm Hg). 3. Normal left ventricular function (ejection fraction \>55%) at baseline (Visit 3). 4. Able to perform bicycle exercise. 5. Able to read, understand and sign the informed consent after the nature of the study has been explained. 6. If sexually active, the patient agrees to use reliable contraception while participating in this study. If a woman, is surgically sterilized or post-menopausal, or has a negative serum pregnancy test.
Exclusion criteria
1. Aortic stenosis, prior known coronary artery disease (including myocardial infarction), cerebrovascular accident, or peripheral vascular disease. 2. Uncontrolled hypertension (SBP \> 200/ DBP \> 95 mm Hg). 3. Atrial fibrillation, diabetes mellitus treated with insulin, or chronic lung disease. 4. Any additional condition(s) which, in the opinion of the investigator, would prohibit the patient from completing the study, or not be in the best interest of the patient. 5. Treatment with nitrates, or a change in antihypertensive medications within the last 1 month. 6. Treatment with any investigational drug within 1 month prior to study drug administration. 7. Previous exposure to alagebrium. 8. AST (SGOT) or ALT (SGPT) \> 2x normal limit. 9. Serum creatinine \> 2.0 ng/mL. 10. Cigar/cigarette smoking. 11. Necessity to use smokeless tobacco or nicotine-containing products, or to consume caffeine, alcohol, or antioxidants starting at midnight prior to study clinic visits. NOTE: Water is allowed ad libitim. 12. Positive drug screen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endothelial function | — |
| Local distensibility | — |
| Arterial stiffening | — |
| Augmentation index (AI) | — |
| Markers of endothelial function, vascular inflammation and collagen synthesis. | — |
Countries
United States
Outcome results
None listed